Sign In
DNA.US
id: 1159

Ginkgo Bioworks (DNA) $17.75 Million Investor Settlement

N.D. California
Court
4:21-cv-08943
Case number
11 May 2021
Class period Start
05 Oct 2021
Class period End

Ginkgo Bioworks agreed to settle $17.75 million with $DNA investors to end the claims over misclassifying and underreporting related party revenue to conceal the Company’s near-total dependence on related parties before and after going public.

Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.1
Filing date
18 November 2021
Lead Plaintiff Deadline
18 January 2022
Plaintiffs
Kevin Stuart
Attorneys
Pomerantz LLP (Chicago, IL), The Schall Law Firm (Los Angeles, CA)
Defendants
Harry E. Sloan, Eli Baker, Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar, Anna Marie Wagner
Judge
Hon. Yvonne Gonzalez Rogers
Administrator
Strategic Claims Services
Settlement agreement date
2024-04-10
Trades matching type
FIFO
+$17,750,000
Total Settlement Amount

Frequently Asked Questions

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of...

    Ticker
    DNA.US
    ISIN
    US37611X1000
    CIK
    0001830214
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    27 Drydock Avenue, Boston, MA, United States, 02210